Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system
Open Access
- 11 July 2011
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 25 (10) , 3505-3518
Abstract
Several diseases of the nervous system are characterized by neurodegeneration and death in childhood. Conventional medicine is ineffective, but fetal or neonatal gene therapy may provide an alternative route to treatment. We evaluated the ability of single‐stranded and self‐complementary adeno‐associated virus pseudotype 2/9 (AAV2/9) to transduce the nervous system and target gene expression to specific neural cell types following intravenous injection into fetal and neonatal mice, using control uninjected age‐matched mice. Fetal and neonatal administration produced global delivery to the central (brain, spinal cord, and all layers of the retina) and peripheral (myenteric plexus and innervating nerves) nervous system but with different expression profiles within the brain; fetal and neonatal administration resulted in expression in neurons and protoplasmic astrocytes, respectively. Neither single‐stranded nor self‐complementary AAV2/9 triggered a microglia‐mediated immune response following either administration. In summary, intravenous AAV2/9 targets gene expression to specific neural cell types dependent on developmental stage. This represents a powerful tool for studying nervous system development and disease. Furthermore, it may provide a therapeutic strategy for treatment of early lethal genetic diseases, such as Gaucher disease, and for disabling neuropathies, such as preterm brain injury.—Rahim, A. A., Wong, A. M. S., Hoefer, K., Buckley, S. M. K., Mattar, C. N., Cheng, S. H., Chan, J. K. Y., Cooper, J. D., Waddington, S. N. Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of central nervous system cell types and extensive transduction of the nervous system. FASEB J. 25, 3505–3518 (2011). www.fasebj.orgKeywords
Funding Information
- Wellcome Trust (WT089806MA)
- Wellcome Trust (GR079491MA)
- Batten Disease Family Association
- Batten Disease Support and Research Association
This publication has 43 references indexed in Scilit:
- Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9Journal of Biological Chemistry, 2011
- Pericytes are required for blood–brain barrier integrity during embryogenesisNature, 2010
- AAV serotype influences gene transfer in corneal stroma in vivoExperimental Eye Research, 2010
- RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMNNature Biotechnology, 2010
- Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor NeuronsMolecular Therapy, 2009
- Anatomical Characterization of Human Fetal Brain Development with Diffusion Tensor Magnetic Resonance ImagingThe Journal of Neuroscience, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosisExperimental Neurology, 2008
- Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosisNeurobiology of Disease, 2007
- The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9Journal of Virology, 2006